Due to financial pressure, the company issued a fixed plan to save itself. Recently, Laimei Pharmaceutical's issuance plan shows that this issuance is aimed at three specific investors: Zhongheng Group, Zhongheng Tongde and Guangtou Guo Hong. Among them, Zhongheng Group plans to subscribe for about 950 million yuan. After deducting the issuance expenses, 700 million yuan was raised to repay the loan, and the rest was used to supplement the working capital. In this fixed-income plan, the large-scale fundraising of Zhongheng Group has attracted much attention. The reporter of International Finance News noted that as of the announcement date of the plan, Zhongheng Group directly held 36310.5 million shares of Laimei Pharmaceutical, accounting for 4.47% of the total share capital.
However, according to the Voting Rights Entrustment Agreement signed on June 20, 2020, Zhongheng Group will become the largest shareholder of Laimei Pharmaceutical with single voting rights. The data shows that under the pressure of single product structure, Zhongheng Group has accelerated the pace of transformation in recent years. In addition to the acquisition of American pharmaceutical industry, Zhongheng Group also cooperated with Tongde Investment to set up a fund and signed a cooperation agreement with Jingfeng Pharmaceutical. Zhongheng Group believes that if the transaction is successful, Zhongheng Group will be able to exercise control over the American pharmaceutical industry, which will help to enhance Zhongheng Group's profitability and position in the biomedical industry in the future. At the same time, Laimei Pharmaceutical plans to introduce the above platform technologies or products into Guangxi to promote the overall upgrading of Guangxi's biomedical industry.
At present, Laimei Pharmaceutical is heavily in debt. As of February 15, 654.38+88 million shares held by Yu Qiu, the controlling shareholder and actual controller of Laimei Pharmaceutical, have been pledged, accounting for 99.9 1% of the company's shares and 22.7% of the total share capital. Prior to this, the Shenzhen Stock Exchange also inquired about this matter. Based on this, Laimei Pharmaceutical believes that through this non-public offering, the company will further accelerate the introduction of state-owned assets, establish a comprehensive and in-depth strategic cooperative relationship with Zhongheng Group, optimize the company's asset-liability structure, and improve the company's credit level and financing level. At the same time, timely replenishment of funds will be beneficial to the company's business development, further improve the company's profitability and promote the company's long-term healthy and stable development. In addition to the debt problem, the performance of 20 19 enterprises is not optimistic.